






(IN448419)
Benzamide based
HDAC3 selective
inhibitors



NEED

Over 45% of small-molecule drug candidates fail due to poor efficacy and stability during preclinical stages. Toxicity, low bioavailability, and rapid degradation in vivo lead to major financial losses and delayed treatment innovations.

TECHNOLOGY OVERVIEW

This patent discloses a new class of carboxamide-based compounds engineered to improve stability, solubility, and biological activity. Designed for pharmaceutical formulations, these molecules target multiple therapeutic pathways while ensuring compatibility with carriers for streamlined drug development and delivery.

TECHNOLOGY KEY FEATURES

Structural flexibility with functional groups (-NH2, -OH, -F), high solubility potential, compatibility with diverse carriers, tunable activity through substitution, improved stability, minimized toxicity risks, enhanced binding affinity in therapeutic targets.

MARKET ANALYSIS

The global small molecule drug discovery market is projected to grow at a CAGR of 7.1%, reaching \$91.2 billion by 2033, fueled by demand for targeted therapies and chronic disease treatments. [Source: Precedence Research, 2024]

Target Industries

Pharmaceutical Drug Discovery, Biotechnology Research, Specialty Therapeutics. , Pharmaceutical discovery labs, biotech companies specializing in molecule optimization, enterprises focused on targeted therapy formulation and early-phase drug development.

AT A GLANCE

 SDG 3 (Good Health and Well-being), SDG 9 (Industry, Innovation and Infrastructure), SDG 17 (Partnerships for the Goals)

Read more here

Technology is available for licensing/ co-development.

Reach out to Prof. Deepak Chitkara, Coordinator, BITS Technology Enabling Centre,

BITS Pilani Contact Details: tec.bits@pilani.bits-pilani.ac.in, 91 1596-255913

